HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

6-ethyl-3,7-dihydroxycholan-24-ol

a GPBAR1 agonist; structure in first source

Also Known As:

BAR501

Networked: 4 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Polycyclic Compounds: 6
- Fused-Ring Compounds
  - Steroids: 70059
    - Cholestanes
      - Cholestanols: 67
        6-ethyl-3,7-dihydroxycholan-24-ol: 4

Experts

1.	Carino, Adriana: 3 articles (10/2017 - 01/2015)
2.	Cipriani, Sabrina: 3 articles (10/2017 - 01/2015)
3.	Fiorucci, Stefano: 3 articles (10/2017 - 01/2015)
4.	Zampella, Angela: 3 articles (10/2017 - 01/2015)
5.	Biagioli, Michele: 2 articles (10/2017 - 01/2017)
6.	Marchianò, Silvia: 2 articles (10/2017 - 01/2017)
7.	Scarpelli, Paolo: 2 articles (10/2017 - 01/2017)
8.	Monti, Maria Chiara: 1 article (10/2017)
9.	Francisci, Daniela: 1 article (01/2017)
10.	Sorcini, Daniele: 1 article (01/2017)

Related Diseases

1.	Non-alcoholic Fatty Liver Disease 12/01/2023 - "BAR501 might be of utility in the treatment for NAFLD-related CVD." 12/01/2023 - "In this study we have investigated the effect of GPBAR1 activation by BAR501, a selective GPBAR1 agonist, in Apolipoprotein E deficient (ApoE-/-) mice fed a high fat diet and fructose (Western diet), a validated model of NAFLD-associated atherosclerosis. "
2.	Atherosclerosis 12/01/2023 - "In this study we have investigated the effect of GPBAR1 activation by BAR501, a selective GPBAR1 agonist, in Apolipoprotein E deficient (ApoE-/-) mice fed a high fat diet and fructose (Western diet), a validated model of NAFLD-associated atherosclerosis. "
3.	Colitis 01/01/2017 - "In this study, we aimed to determine the role of GPBAR1 in mediating leukocyte trafficking in chemically induced models of colitis and investigate the therapeutic potential of BAR501, a small molecule agonist for GPBAR1. " 01/01/2017 - "Exposure to BAR501 shifted intestinal macrophages from a classically activated (CD11b+, CCR7+, F4/80-) to an alternatively activated (CD11b+, CCR7-, F4/80+) phenotype, reduced the expression of inflammatory genes (TNF-α, IFN-γ, IL-1β, IL-6, and CCL2 mRNAs), and attenuated the wasting syndrome and severity of colitis (≈70% reduction in the Colitis Disease Activity Index). "
4.	Insulin Resistance 10/20/2017 - "Treating HFD-F mice with 6β-ethyl-3a,7b-dihydroxy-5b-cholan-24-ol (BAR501), a selective Gpbar1-ligand, reversed insulin resistance and histologic features of NASH, increased the weight of epWAT and BAT functionality and promoted energy expenditure and the browning of epWAT as assessed by measuring expression of Ucp1 and Pgc-1α. " 12/01/2023 - "Treating ApoE-/- mice with BAR501, 30 mg/kg for 14 weeks, attenuated the body weight gain while ameliorated the insulin sensitivity by increasing the plasma concentrations of GLP-1 and FGF15. "
5.	Wasting Syndrome (Wasting Disease) 01/01/2017 - "Exposure to BAR501 shifted intestinal macrophages from a classically activated (CD11b+, CCR7+, F4/80-) to an alternatively activated (CD11b+, CCR7-, F4/80+) phenotype, reduced the expression of inflammatory genes (TNF-α, IFN-γ, IL-1β, IL-6, and CCL2 mRNAs), and attenuated the wasting syndrome and severity of colitis (≈70% reduction in the Colitis Disease Activity Index). "

Related Drugs and Biologics

1.	Fructose
2.	Apolipoproteins E (ApoE)
3.	Apolipoproteins
4.	Glucagon-Like Peptide 1 (GLP 1)
5.	Trinitrobenzenesulfonic Acid
6.	Oxazolone